Tavapadon Conference Call
Video Presentation Download Presentation Transcript Download Transcript
DRI Healthcare Announces US$316 Million Purchase of Tavapadon Royalty
– DRI Healthcare to acquire royalty participation rights on tavapadon for an aggregate purchase price of US$316 million upon FDA approval of tavapadon –– Tavapadon is a novel oral dopamine-D1R/D5R partial agonist that has been submitted to the FDA for approval for the treatment of Parkinson’s disease –– DRI Healthcare to host investor call on Monday, September […]